Lower urinary tract symptoms (LUTS) remain one of the most prevalent and disabling clinical manifestations in multiple sclerosis (MS) patients, often emerging early in the disease course and ...
Andrew Hahn discusses the LenCabo study, a randomized phase 2 trial comparing lenvatinib plus everolimus versus cabozantinib for metastatic clear cell renal cell carcinoma progressing on PD-1 ...
At the World Congress of Endourology and Uro-Technology, Kriselle Madamba presented research on antibiotic-augmented irrigation using neomycin and polymyxin B during ureteroscopy to reduce ...
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Read the Full Video Transcript Ashish Kamat: Hello everybody, and welcome to UroToday's Bladder Cancer Center of Excellence. I'm Ashish Kamat, professor of urologic oncology at M.D. Anderson Cancer ...
Read the Full Video Transcript Sue Yom: Hi, everybody. As they say on the Monty Python show, “And now for something completely different.” I do appreciate the engagement of patient concerns, and I ...
Sam Chang speaks with Sarah Psutka about an expanded access program for cretostimogene (CG0070) in BCG-unresponsive non-muscle invasive bladder cancer. Dr. Psutka explains that this oncolytic ...
Neeraj Agarwal speaks with Soumyajit Roy about comparing radiation therapy with surgery for localized high-risk prostate cancer. Dr. Roy discusses his systematic analysis of two major trials—CALGB ...
Alicia Morgans is joined by Robert Thomas to discuss a study on gut microbiome and prostate cancer. This double-blind randomized trial involving 220 men with mostly low-risk but progressing prostate ...
Umang Swami joins Alicia Morgans to discuss real-world bone health agent utilization in metastatic castration-resistant prostate cancer. Analyzing the Flatiron Health database of 14,000 mCRPC patients ...
Ramy Saleh joins Neeraj Agarwal to discuss the ACCEL trial, examining Actinium-255-PSMA-62 in oligometastatic hormone-sensitive and metastatic castration-resistant prostate cancer. This trial combines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results